Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. (NCT05389267)

🧪 Interventions in This Study

• Kinezodianone R hydrochloride (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Dr EL-HARAZI — Glendale, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Glaucoma

• Novel Markers for Detecting Early Progression of Glaucoma — Halifax, Nova Scotia
• Electrical Stimulation for the Treatment of Glaucoma — Palo Alto, California
• Visual Field Analysis With Artificial Intelligence — Alexandria, Virginia
• Anterior Segment Optical Coherence Tomography Microstent Positioning — Murray, Utah
• Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination — Santa Rosa de Copán,
• Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. — Glendale, Arizona

Explore by condition: All Glaucoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.